Is Revolution Medicines a Good Stock to Own?
Though it’s still quite early in the year, pharmaceutical startup…
Buy
73
SLS Quote, Financials, Valuation and Earnings
Last price:
$3.99
Seasonality move
:
5.95%
Day range:
$3.69 - $4.10
52-week range:
$0.85 - $5.18
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
14.85x
Volume:
7.9M
Avg. volume:
11.7M
1-year change:
304.97%
Market cap:
$677.7M
Revenue:
--
EPS (TTM):
-$0.29
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
SLS
SELLAS Life Sciences Group, Inc.
|
-- | -$0.06 | -- | -30.48% | $6.83 |
|
ADMA
ADMA Biologics, Inc.
|
$139.8M | $0.20 | 26.61% | 81.82% | $25.67 |
|
FOLD
Amicus Therapeutics, Inc.
|
$179.8M | $0.16 | 20.08% | 234.42% | $14.83 |
|
GERN
Geron Corp.
|
$50.9M | -$0.05 | 7.03% | -8.38% | $3.60 |
|
GTBP
GT Biopharma, Inc.
|
-- | -- | -- | -- | $8.00 |
|
VNDA
Vanda Pharmaceuticals, Inc.
|
$59.3M | -- | 23.5% | -- | $13.63 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
SLS
SELLAS Life Sciences Group, Inc.
|
$3.98 | $6.83 | $677.7M | -- | $0.00 | 0% | -- |
|
ADMA
ADMA Biologics, Inc.
|
$17.31 | $25.67 | $4.1B | 20.33x | $0.00 | 0% | 8.71x |
|
FOLD
Amicus Therapeutics, Inc.
|
$14.33 | $14.83 | $4.4B | -- | $0.00 | 0% | 7.33x |
|
GERN
Geron Corp.
|
$1.31 | $3.60 | $836.2M | -- | $0.00 | 0% | 4.76x |
|
GTBP
GT Biopharma, Inc.
|
$0.75 | $8.00 | $7.9M | -- | $0.00 | 0% | 59.35x |
|
VNDA
Vanda Pharmaceuticals, Inc.
|
$7.47 | $13.63 | $441.5M | -- | $0.00 | 0% | 2.07x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
SLS
SELLAS Life Sciences Group, Inc.
|
1.3% | 0.623 | 0.3% | 7.50x |
|
ADMA
ADMA Biologics, Inc.
|
16.16% | -3.305 | 2.38% | 3.53x |
|
FOLD
Amicus Therapeutics, Inc.
|
65.77% | -0.323 | 18.22% | 1.91x |
|
GERN
Geron Corp.
|
50.25% | 1.450 | 28.73% | 4.76x |
|
GTBP
GT Biopharma, Inc.
|
-- | -0.132 | 4.06% | 1.98x |
|
VNDA
Vanda Pharmaceuticals, Inc.
|
2.29% | -0.960 | 3.7% | 2.92x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
SLS
SELLAS Life Sciences Group, Inc.
|
-- | -$7.1M | -100.8% | -103.86% | -- | -$7.1M |
|
ADMA
ADMA Biologics, Inc.
|
$75.6M | $51M | 47.04% | 58.71% | 38.01% | -$1.1M |
|
FOLD
Amicus Therapeutics, Inc.
|
$147.7M | $34.3M | -2.18% | -7.02% | 20.27% | $35.3M |
|
GERN
Geron Corp.
|
$45.9M | -$13.9M | -16.45% | -29.65% | -29.41% | -$13.5M |
|
GTBP
GT Biopharma, Inc.
|
-- | -$3.4M | -626.24% | -626.24% | -- | -$3.7M |
|
VNDA
Vanda Pharmaceuticals, Inc.
|
$51.6M | -$31.3M | -16.2% | -16.55% | -55.61% | -$31.8M |
SELLAS Life Sciences Group, Inc. vs. Competitors
-
Which has Higher Returns SLS or ADMA?
ADMA Biologics, Inc. has a net margin of -- compared to SELLAS Life Sciences Group, Inc.'s net margin of 27.14%. SELLAS Life Sciences Group, Inc.'s return on equity of -103.86% beat ADMA Biologics, Inc.'s return on equity of 58.71%.
Company Gross Margin Earnings Per Share Invested Capital SLSSELLAS Life Sciences Group, Inc.-- -$0.06 $46.2M ADMAADMA Biologics, Inc.56.32% $0.15 $514.3M -
What do Analysts Say About SLS or ADMA?
SELLAS Life Sciences Group, Inc. has a consensus price target of $6.83, signalling upside risk potential of 71.69%. On the other hand ADMA Biologics, Inc. has an analysts' consensus of $25.67 which suggests that it could grow by 48.28%. Given that SELLAS Life Sciences Group, Inc. has higher upside potential than ADMA Biologics, Inc., analysts believe SELLAS Life Sciences Group, Inc. is more attractive than ADMA Biologics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings SLSSELLAS Life Sciences Group, Inc.2 0 0 ADMAADMA Biologics, Inc.3 0 0 -
Is SLS or ADMA More Risky?
SELLAS Life Sciences Group, Inc. has a beta of 2.262, which suggesting that the stock is 126.208% more volatile than S&P 500. In comparison ADMA Biologics, Inc. has a beta of 0.466, suggesting its less volatile than the S&P 500 by 53.393%.
-
Which is a Better Dividend Stock SLS or ADMA?
SELLAS Life Sciences Group, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ADMA Biologics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. SELLAS Life Sciences Group, Inc. pays -- of its earnings as a dividend. ADMA Biologics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SLS or ADMA?
SELLAS Life Sciences Group, Inc. quarterly revenues are --, which are smaller than ADMA Biologics, Inc. quarterly revenues of $134.2M. SELLAS Life Sciences Group, Inc.'s net income of -$6.8M is lower than ADMA Biologics, Inc.'s net income of $36.4M. Notably, SELLAS Life Sciences Group, Inc.'s price-to-earnings ratio is -- while ADMA Biologics, Inc.'s PE ratio is 20.33x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for SELLAS Life Sciences Group, Inc. is -- versus 8.71x for ADMA Biologics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SLSSELLAS Life Sciences Group, Inc.-- -- -- -$6.8M ADMAADMA Biologics, Inc.8.71x 20.33x $134.2M $36.4M
-
Which has Higher Returns SLS or FOLD?
Amicus Therapeutics, Inc. has a net margin of -- compared to SELLAS Life Sciences Group, Inc.'s net margin of 10.24%. SELLAS Life Sciences Group, Inc.'s return on equity of -103.86% beat Amicus Therapeutics, Inc.'s return on equity of -7.02%.
Company Gross Margin Earnings Per Share Invested Capital SLSSELLAS Life Sciences Group, Inc.-- -$0.06 $46.2M FOLDAmicus Therapeutics, Inc.87.38% $0.06 $673.2M -
What do Analysts Say About SLS or FOLD?
SELLAS Life Sciences Group, Inc. has a consensus price target of $6.83, signalling upside risk potential of 71.69%. On the other hand Amicus Therapeutics, Inc. has an analysts' consensus of $14.83 which suggests that it could grow by 3.51%. Given that SELLAS Life Sciences Group, Inc. has higher upside potential than Amicus Therapeutics, Inc., analysts believe SELLAS Life Sciences Group, Inc. is more attractive than Amicus Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings SLSSELLAS Life Sciences Group, Inc.2 0 0 FOLDAmicus Therapeutics, Inc.2 5 0 -
Is SLS or FOLD More Risky?
SELLAS Life Sciences Group, Inc. has a beta of 2.262, which suggesting that the stock is 126.208% more volatile than S&P 500. In comparison Amicus Therapeutics, Inc. has a beta of 0.417, suggesting its less volatile than the S&P 500 by 58.311%.
-
Which is a Better Dividend Stock SLS or FOLD?
SELLAS Life Sciences Group, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Amicus Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. SELLAS Life Sciences Group, Inc. pays -- of its earnings as a dividend. Amicus Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SLS or FOLD?
SELLAS Life Sciences Group, Inc. quarterly revenues are --, which are smaller than Amicus Therapeutics, Inc. quarterly revenues of $169.1M. SELLAS Life Sciences Group, Inc.'s net income of -$6.8M is lower than Amicus Therapeutics, Inc.'s net income of $17.3M. Notably, SELLAS Life Sciences Group, Inc.'s price-to-earnings ratio is -- while Amicus Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for SELLAS Life Sciences Group, Inc. is -- versus 7.33x for Amicus Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SLSSELLAS Life Sciences Group, Inc.-- -- -- -$6.8M FOLDAmicus Therapeutics, Inc.7.33x -- $169.1M $17.3M
-
Which has Higher Returns SLS or GERN?
Geron Corp. has a net margin of -- compared to SELLAS Life Sciences Group, Inc.'s net margin of -39.02%. SELLAS Life Sciences Group, Inc.'s return on equity of -103.86% beat Geron Corp.'s return on equity of -29.65%.
Company Gross Margin Earnings Per Share Invested Capital SLSSELLAS Life Sciences Group, Inc.-- -$0.06 $46.2M GERNGeron Corp.97.13% -$0.03 $500M -
What do Analysts Say About SLS or GERN?
SELLAS Life Sciences Group, Inc. has a consensus price target of $6.83, signalling upside risk potential of 71.69%. On the other hand Geron Corp. has an analysts' consensus of $3.60 which suggests that it could grow by 174.81%. Given that Geron Corp. has higher upside potential than SELLAS Life Sciences Group, Inc., analysts believe Geron Corp. is more attractive than SELLAS Life Sciences Group, Inc..
Company Buy Ratings Hold Ratings Sell Ratings SLSSELLAS Life Sciences Group, Inc.2 0 0 GERNGeron Corp.3 1 1 -
Is SLS or GERN More Risky?
SELLAS Life Sciences Group, Inc. has a beta of 2.262, which suggesting that the stock is 126.208% more volatile than S&P 500. In comparison Geron Corp. has a beta of 0.594, suggesting its less volatile than the S&P 500 by 40.567%.
-
Which is a Better Dividend Stock SLS or GERN?
SELLAS Life Sciences Group, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Geron Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. SELLAS Life Sciences Group, Inc. pays -- of its earnings as a dividend. Geron Corp. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SLS or GERN?
SELLAS Life Sciences Group, Inc. quarterly revenues are --, which are smaller than Geron Corp. quarterly revenues of $47.2M. SELLAS Life Sciences Group, Inc.'s net income of -$6.8M is higher than Geron Corp.'s net income of -$18.4M. Notably, SELLAS Life Sciences Group, Inc.'s price-to-earnings ratio is -- while Geron Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for SELLAS Life Sciences Group, Inc. is -- versus 4.76x for Geron Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SLSSELLAS Life Sciences Group, Inc.-- -- -- -$6.8M GERNGeron Corp.4.76x -- $47.2M -$18.4M
-
Which has Higher Returns SLS or GTBP?
GT Biopharma, Inc. has a net margin of -- compared to SELLAS Life Sciences Group, Inc.'s net margin of --. SELLAS Life Sciences Group, Inc.'s return on equity of -103.86% beat GT Biopharma, Inc.'s return on equity of -626.24%.
Company Gross Margin Earnings Per Share Invested Capital SLSSELLAS Life Sciences Group, Inc.-- -$0.06 $46.2M GTBPGT Biopharma, Inc.-- -$0.83 $3M -
What do Analysts Say About SLS or GTBP?
SELLAS Life Sciences Group, Inc. has a consensus price target of $6.83, signalling upside risk potential of 71.69%. On the other hand GT Biopharma, Inc. has an analysts' consensus of $8.00 which suggests that it could grow by 972.67%. Given that GT Biopharma, Inc. has higher upside potential than SELLAS Life Sciences Group, Inc., analysts believe GT Biopharma, Inc. is more attractive than SELLAS Life Sciences Group, Inc..
Company Buy Ratings Hold Ratings Sell Ratings SLSSELLAS Life Sciences Group, Inc.2 0 0 GTBPGT Biopharma, Inc.1 0 0 -
Is SLS or GTBP More Risky?
SELLAS Life Sciences Group, Inc. has a beta of 2.262, which suggesting that the stock is 126.208% more volatile than S&P 500. In comparison GT Biopharma, Inc. has a beta of 1.172, suggesting its more volatile than the S&P 500 by 17.17%.
-
Which is a Better Dividend Stock SLS or GTBP?
SELLAS Life Sciences Group, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. GT Biopharma, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. SELLAS Life Sciences Group, Inc. pays -- of its earnings as a dividend. GT Biopharma, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SLS or GTBP?
SELLAS Life Sciences Group, Inc. quarterly revenues are --, which are smaller than GT Biopharma, Inc. quarterly revenues of --. SELLAS Life Sciences Group, Inc.'s net income of -$6.8M is lower than GT Biopharma, Inc.'s net income of -$3.1M. Notably, SELLAS Life Sciences Group, Inc.'s price-to-earnings ratio is -- while GT Biopharma, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for SELLAS Life Sciences Group, Inc. is -- versus 59.35x for GT Biopharma, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SLSSELLAS Life Sciences Group, Inc.-- -- -- -$6.8M GTBPGT Biopharma, Inc.59.35x -- -- -$3.1M
-
Which has Higher Returns SLS or VNDA?
Vanda Pharmaceuticals, Inc. has a net margin of -- compared to SELLAS Life Sciences Group, Inc.'s net margin of -40.15%. SELLAS Life Sciences Group, Inc.'s return on equity of -103.86% beat Vanda Pharmaceuticals, Inc.'s return on equity of -16.55%.
Company Gross Margin Earnings Per Share Invested Capital SLSSELLAS Life Sciences Group, Inc.-- -$0.06 $46.2M VNDAVanda Pharmaceuticals, Inc.91.64% -$0.38 $476.9M -
What do Analysts Say About SLS or VNDA?
SELLAS Life Sciences Group, Inc. has a consensus price target of $6.83, signalling upside risk potential of 71.69%. On the other hand Vanda Pharmaceuticals, Inc. has an analysts' consensus of $13.63 which suggests that it could grow by 82.4%. Given that Vanda Pharmaceuticals, Inc. has higher upside potential than SELLAS Life Sciences Group, Inc., analysts believe Vanda Pharmaceuticals, Inc. is more attractive than SELLAS Life Sciences Group, Inc..
Company Buy Ratings Hold Ratings Sell Ratings SLSSELLAS Life Sciences Group, Inc.2 0 0 VNDAVanda Pharmaceuticals, Inc.3 1 0 -
Is SLS or VNDA More Risky?
SELLAS Life Sciences Group, Inc. has a beta of 2.262, which suggesting that the stock is 126.208% more volatile than S&P 500. In comparison Vanda Pharmaceuticals, Inc. has a beta of 0.604, suggesting its less volatile than the S&P 500 by 39.647%.
-
Which is a Better Dividend Stock SLS or VNDA?
SELLAS Life Sciences Group, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Vanda Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. SELLAS Life Sciences Group, Inc. pays -- of its earnings as a dividend. Vanda Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SLS or VNDA?
SELLAS Life Sciences Group, Inc. quarterly revenues are --, which are smaller than Vanda Pharmaceuticals, Inc. quarterly revenues of $56.3M. SELLAS Life Sciences Group, Inc.'s net income of -$6.8M is higher than Vanda Pharmaceuticals, Inc.'s net income of -$22.6M. Notably, SELLAS Life Sciences Group, Inc.'s price-to-earnings ratio is -- while Vanda Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for SELLAS Life Sciences Group, Inc. is -- versus 2.07x for Vanda Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SLSSELLAS Life Sciences Group, Inc.-- -- -- -$6.8M VNDAVanda Pharmaceuticals, Inc.2.07x -- $56.3M -$22.6M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Has Vistra Stock Gone Up?
Integrated power generation business Vistra (NYSE:VST) surprised investors recently when…
Why Is Amkor Stock Up So Much?
Semiconductor packaging and testing major Amkor (NASDAQ:AMKR) has started 2026…
Stock Ideas
Buy
56
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 63x
Buy
59
Is GOOG Stock a Buy?
Market Cap: $4T
P/E Ratio: 41x
Sell
48
Is GOOGL Stock a Buy?
Market Cap: $4T
P/E Ratio: 41x
Alerts
Buy
75
AGX alert for Jan 17
Argan, Inc. [AGX] is up 16.4% over the past day.
Buy
80
ASTS alert for Jan 17
AST Spacemobile, Inc. [ASTS] is up 14.32% over the past day.
Buy
84
IREN alert for Jan 17
IREN Ltd. [IREN] is up 11.35% over the past day.
